Evotec

from Wikipedia, the free encyclopedia
Evotec SE

logo
legal form Societas Europaea
ISIN DE0005664809
founding 1993
Seat Hamburg , GermanyGermanyGermany 
management
Number of employees 3,030
sales 446.4 million euros (2019)
Branch biotechnology
Website www.evotec.com
As of December 31, 2019

The Evotec SE with headquarters in Hamburg is a drug discovery and development that generates new discovery alliance and development partnerships with pharmaceutical and biotechnology companies approaches to the development of pharmaceutical products.

Overview

The company operates worldwide and offers integrated solutions in the field of drug discovery. The company conducts its operating business in the two segments EVT Execute and EVT Innovate. EVT Execute provides stand-alone or integrated drug discovery and development solutions based on its customers' intellectual property. All activities from target to clinical development are covered.

In the EVT Innovate segment, the company develops its own drug discovery projects, research products and platforms, partly in collaboration with partners. Evotec is also founding BRIDGEs (Biomedical Research, Innovation & Development Generation Efficiency) under its EVT Innovate segment, partnerships with academic institutions whose aim is to transfer scientific research projects into the development of pharmaceutical active ingredients.

Evotec employs around 2,000 scientists and works with technologies in the areas of CNS / neurology such as Alzheimer's , Huntington 's disease , metabolic diseases such as diabetes , cancer , inflammatory diseases and infectious diseases. The company works in long-term research alliances with international partners such as Bayer HealthCare , Sanofi , Boehringer Ingelheim , CHDI Foundation, Genentech , MedImmune / AstraZeneca , Hoffmann-La Roche and UCB . In addition, the company has development partnerships with pharmaceutical companies and its own drug candidates that are in clinical and preclinical development.

The company has been listed in the TecDAX since October 28, 2009 , and was also included in the MDAX on September 24, 2018 .

history

In 1993 the biotechnology company was founded as Evotec BioSystems in Hamburg . The founders were the Nobel Prize winner Manfred Eigen and the scientists Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte , Rudolf Rigler and Charles Weissmann . When it was founded, the company was a "spin-off" from the Max Planck Institute for Biophysical Chemistry , Göttingen.

In the first few years, the ultra- high throughput screening system (EVOscreen®) was developed with Evotec in cooperation with international pharmaceutical companies such as Novartis and SmithKlineBeecham . In 1999 Evotec BioSystems went public (Deutsche Börse: EVT) and one year later took over the British company Oxford Asymmetry International plc , which provides chemical services for international biotechnology and pharmaceutical companies, and became Evotec OAI AG . In 2005 the name was changed to Evotec AG . In April 2019 Evotec announced the conversion into a Societas Europaea .

In 2002 the company was divided into two business areas, on the one hand "Discovery and Development Services", on the other hand "Tools and Technologies" (instruments and technologies). The Evotec Technologies GmbH was founded this year, but in 2006 at Perkin Elmer sold to the remaining company on its core business, the research and development focus of new pharmaceutical agents. In 2008, Evotec acquired Renovis, a US biotechnology company, and was listed on the Nasdaq . A year later, Evotec voluntarily decided not to list its American Depositary Receipts on the NASDAQ in order to streamline its business activities and concentrate the liquidity of Evotec shares on one trading platform (TecDax), thereby reducing costs. In addition, in 2009 Evotec acquired 70% of Research Support International Limited (RSIPL), a service provider in the field of synthetic chemistry, and the zebrafish screening business of India's Summit Corporation .

In 2010 Evotec took over DeveloGen AG , a company specializing in research into therapies for the treatment of metabolic diseases (such as diabetes), and in 2011 two other companies: Kinaxo Biotechnologies GmbH , a private biotechnology company based in Munich , and the Compound Management business of BioFocus , a Galapagos Group company . Kinaxo has proprietary technologies that are used to improve drug development throughout the drug development process.

On July 30, 2017, the Aptuit company in the USA was taken over for EUR 256 million.

Alliances / partnerships

Drug discovery alliances

Development partnerships

Technology partner

  • C4X Discovery
  • Chem Bridge Corporation
  • Diamond Light Source
  • Hypha Discovery
  • IR Pharma
  • PsychoGenics Inc.
  • Reach separations

Locations

Germany

Hamburg (headquarters), Göttingen & Munich , Martinsried

  • Hit identification
  • in vitro & in vivo biology
  • Chemical proteomics & biomarker research and validation
  • Cell and Protein Production
  • Antibody research

United States

Princeton , Branford & Watertown

  • Substance management
  • QC and storage of substances
  • Cell and Protein Production
  • ADME-Tox & DMPK

France

Toulouse

  • Substance management
  • Hit identification
  • in vitro & in vivo oncology
  • Medicinal chemistry
  • ADME & PK
  • Cell, Antibody & Protein Production

Great Britain

Abingdon , Alderley Park

  • Medicinal chemistry
  • ADME-Tox & DMPK
  • Structural biology
  • in vitro & in vivo anti-infectives platform / screening
  • Process development
  • CMC and commercial manufacture
  • Pre-formulation

Italy & Switzerland

Verona , Reinach

  • Hit identification
  • in vitro & in vivo biology
  • Medicinal chemistry
  • ADME-Tox, DMPK
  • Biomarker research and validation
  • Indigo
  • CMC

Board of Directors and Supervisory Board

Board

  • Werner Lanthaler (Chief Executive Officer)
  • Enno Spillner (Chief Financial Officer)
  • Cord Dohrmann (Chief Scientific Officer)
  • Craig Johnstone (Chief Operating Officer)

Supervisory board

  • Wolfgang Plischke (Chairman)
  • Claus Braestrup
  • Bernd Hirsch
  • Iris Löw-Friedrich
  • Michael Shalmi
  • Elaine Sullivan

Web links

Individual evidence

  1. ↑ a b Annual Report 2019. Evotec SE, March 26, 2020, accessed on June 19, 2020 .
  2. ↑ Overview Index Changes (from September 24, 2018). (PDF) Deutsche Börse , September 5, 2018, archived from the original on September 6, 2018 ; accessed on September 5, 2018 .
  3. ↑ see page Innovative spin-offs on "Max Planck Innovation" , accessed April 21, 2020. Max Planck Innovation GmbH is the subsidiary for technology transfer of the Max Planck Society
  4. ↑ Evotec AG: Press release: Annual General Meeting of Evotec OAI Approves Cash Capital Increase and Changes in Supervisory Board, June 7, 2005, accessed September 20, 2010.
  5. ↑ Evotec SE: Press release: Evotec AG completes conversion to Evotec SE. Retrieved April 4, 2019 .
  6. ↑ Evotec OAI: Annual Report 2002
  7. ↑ Evotec AG: Annual Report 2009.
  8. ↑ Evotec completes acquisition of Aptuit. (No longer available online.) Archived from the original on August 16, 2017 ; accessed on August 16, 2017 .
  9. ↑ DGAP-News: Bayer and Evotec form new strategic alliance with focus on polycystic ovarian syndrome. In: FinanzNachrichten.de. January 9, 2020, accessed June 19, 2020 .
  10. ↑ Transcript: Evotec starts Sanofi alliance. Biocom AG, archived from the original on September 28, 2015 ; accessed on March 20, 2015 .